Rakesh Dixit
President & Chief Executive Officer Bionavigen Oncology
Seminars
Thursday 6th November 2025
Workshop highlights include:
- Contrasting predictive value of CDX and PDX in vivo models, contextualized with time and investment available for preclinical studiesÂ
- Diving into takeaways of ADC translation: what was the most useful results gained from preclinical studies?Â
- Debating considerations for the translation of bispecific ADCs
- Laying out rationale for selecting ADC combinations and delving into preclinical characterization to best predict clinical activity
Monday 3rd November 2025
Evaluating Toxicity Considerations & Challenges of Dual Payload & Bispecific Drug Conjugates
9:30 am
- Contextualizing concepts from emerging novel conjugates: Dual payload ADCs and bispecific ADCs
- Considering factors for balancing DAR and combining mechanisms for dual payload toxicity profiles
- Evaluating the ongoing development and promise of bispecific ADC programs
Tuesday 4th November 2025
Chair:
Download the Full Event Guide for full details
Monday 3rd November 2025
Chair:
Despite blockbuster ADCs moving to earlier-line treatments and challenging oncology standard of care, poor tolerability remains the limiting factor to widen therapeutic index and achieve true success in patients.
Don’t miss this seminar day utilizing in vivo and in vitro models to predict ADC clinical safety profiles, characterizing and mitigating on and off-target ADC toxicities, and spotlighting ADC design with enhanced tolerability profiles
Download the Full Event Guide for full details
